Talphera, Inc. Files Q3 2024 10-Q

TL;DR

Talphera's Q3 2024 10-Q is in. Financials and equity details are out.

AI Summary

Talphera, Inc. (formerly AcelRx Pharmaceuticals Inc.) filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter of 2024. Key financial instruments like warrants and RSUs are mentioned in relation to equity compensation and financing activities.

Why It Matters

This filing provides investors with the latest financial health and operational status of Talphera, Inc., crucial for understanding its current market position and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Talphera faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this excerpt but are typical for the industry.

Key Numbers

• 2024-09-30 — Reporting Period End (The 10-Q covers financial data up to this date.)
• 2024-11-13 — Filing Date (The date the report was submitted to the SEC.)

Key Players & Entities

• TALPHERA, INC. (company) — Filer
• ACELRX PHARMACEUTICALS INC (company) — Former company name
• 2024-09-30 (date) — Reporting period end date
• 2024-11-13 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ge on Which Registered: Common Stock, $0.001 par value TLPH The Nasdaq Global Ma

Filing Documents

• acrx20240930_10q.htm (10-Q) — 1417KB
• ex_742984.htm (EX-31.1) — 8KB
• ex_742985.htm (EX-31.2) — 8KB
• ex_742986.htm (EX-32.1) — 6KB
• 0001437749-24-034965.txt ( ) — 6114KB
• tlph-20240930.xsd (EX-101.SCH) — 54KB
• tlph-20240930_def.xml (EX-101.DEF) — 379KB
• tlph-20240930_lab.xml (EX-101.LAB) — 324KB
• tlph-20240930_pre.xml (EX-101.PRE) — 401KB
• tlph-20240930_cal.xml (EX-101.CAL) — 35KB
• acrx20240930_10q_htm.xml (XML) — 922KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 5 Item 1.

Financial Statements

Financial Statements 5 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (unaudited) 5 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited) 6 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited) 7 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited) 8 Notes to Condensed Consolidated Financial Statements (unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

OTHER INFORMATION

PART II. OTHER INFORMATION 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55 Item 3. Defaults Upon Senior Securities 55 Item 4. Mine Safety Disclosures 55 Item 5. Other Information 55 Item 6. Exhibits 56 Unless the context indicates otherwise, the terms "Talphera," "we," "us" and "our" refer to Talphera, Inc., and its consolidated subsidiary. "Niyad" and "Fedsyra" are trademarks, and "Zalviso" are registered trademarks, all owned by Talphera, Inc. This Quarterly Report also contains trademarks and trade names that are the property of their respective owners. 2

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q, or Form 10-Q, contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by that section. The forward-looking statements in this Form 10-Q are contained principally under "Part I. Financial Information - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Part II. Other Information - Item 1A. Risk Factors". In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Many important factors affect our ability to achieve our objectives, including: our ability to obtain additional required financing and to continue as a going concern; our ability to manage our operating costs and reduce our cash burn; the accuracy of our estimates regarding the sufficiency of our cash resources, future revenues, expenses, and capital requirements; our ability to maintain listing of our securities trading on the Nasdaq exchange; the historical performance and high volatility in the market price o

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Talphera, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share and per share data) September 30, 2024 December 31, 2023 (1) Assets Current Assets: Cash and cash equivalents $ 11,117 $ 5,721 Short-term investments — 3,660 Prepaid expenses and other current assets 1,078 2,195 Total current assets 12,195 11,576 In-process research and development asset 8,819 8,819 Total assets $ 21,014 $ 20,395 Liabilities and Stockholders ' Equity Current Liabilities: Accounts payable $ 396 $ 1,336 Accrued and other liabilities 1,643 2,445 Liabilities of discontinued operations, current portion 723 731 Total current liabilities 2,762 4,512 Warrant liability 2,084 1,778 Liability related to the sale of future payments 6,527 — Total liabilities 11,373 6,290 Commitments and Contingencies Stockholders' Equity: Common stock, $ 0.001 par value— 200,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 17,026,313 and 16,952,519 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 17 17 Additional paid-in capital 464,984 458,314 Accumulated deficit ( 455,360 ) ( 444,226 ) Total stockholders' equity 9,641 14,105 Total Liabilities and Stockholders' Equity $ 21,014 $ 20,395 (1) The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. See notes to condensed consolidated financial statements. 5 Talphera, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue $ — $ 117 $ — $ 370 Operating costs and expenses:

View Full Filing

View this 10-Q filing on SEC EDGAR